Abstract
Pathological markers of hypoxia
Hypoxia is defined as a partial pressure of oxygen below that required for normal cellular functions [34] . This is a physiological definition, which can only truly be assessed in patients by the invasive monitoring of cancers before they are resected. For example, the pO2 in cervical cancer has been measured using an oxygen electrode [35, 36] . Data from four of five independent studies suggest that a pO2 Յ5 or Յ10 mmHg is associated with a reduced likelihood of disease-free survival in cervical cancer [35, [37] [38] [39] [40] [41] 
Hypoxia inducible factor (HIF) targets

HIF-1 versus HIF-2
Each tumour type has an individual hypoxic response [60] , and the prognostic significance of specific markers varies widely among them. Nevertheless, the transcriptional regulators of hypoxia, HIF-1 and HIF-2, and well described target genes, such as carbonic anhydrase 9 (a HIF-1, but not HIF-2, target) [63, 64] and glucose transporter-1 (a HIF-1 and/or HIF-2 target) [64, 65] , are reported to have prognostic significance in numerous tumour types [33] . The transcriptional response to hypoxia mediated by HIF-1 is distinct from that mediated by HIF-2 [66] , and this is reflected in the heterogeneous hypoxic response in cancer. For example, in breast cancer, the hypoxic response is predominantly mediated through HIF-1 with a minor contribution from HIF-2 [64] . Nuclear HIF-1␣ expression is widely reported to be a significant adverse prognostic factor in breast cancer [67] [68] [69] [70] [71] [72] [68] [69] [70] [71] [72] 74] (unfortunately the dissenting study [73] [75] , is reported to be a good prognostic factor in ductal carcinoma in situ, but a poor prognostic factor in invasive ductal carcinoma [76] . In cervical cancer, HIF-1␣ expression is associated with a trend towards a good prognosis in large tumours, but towards a poor prognosis in small tumours [77] . Perhaps these observations are a reflection of the growth inhibitory effects of HIF-1␣ in vitro (due to direct effects on proliferation and cell death) [11] as opposed to the growth promoting effects of HIF-1␣ in vivo (due to effects on angiogenesis and metastasis) [78] . Alternatively, they may be due to differences in the relative contribution of acute hypoxia ( [68] [69] [70] [71] [72] 74] 
Early versus late stage cancer
To confuse matters further, certain hypoxia markers have been reported to have different prognostic significance in pre-invasive versus invasive lesions; BNIP3 (a HIF-1 target gene and a proapoptotic member of the Bcl-2 gene family)
due to transient ischemia, secondary to dysfunctional angiogenesis; frequently co-existing with reperfusion injury) versus chronic hypoxia (due to cells existing at the limits of oxygen diffusion) in
Fig. 1 (A) A forest plot of the prognostic significance of HIF-1␣ in published multivariate analyses of disease free survival in breast cancer
. (B) A funnel plot of the studies described in (A).
driving HIF-1␣ expression. There is biological evidence to suggest that acute hypoxia has a greater effect on promoting tumour metastasis than chronic hypoxia [79] . Moreover, the presence of HIF-1␣ in acute hypoxia provides a selective advantage to neoplastic cells, but in chronic hypoxia HIF-1␣ expression may promote necrosis of the tumour [80] . In another preclinical model, prolonged hypoxia was associated with increased radiosensitivity (versus normoxia), as opposed to the resistance to radiotherapy conferred by intermittent hypoxia [81] . One may hypothesize that this difference is due to modulation of the HIF-1 transcriptional program in acute versus chronic hypoxia; perhaps due to differences in microenvironmental conditions, such as pH [82] .
Intratumour heterogeneity
Hypoxia and expression of hypoxia markers, is heterogeneous throughout tumours (Fig. 2) . Therefore, it is crucial that the appropriate regions of whole sections are assessed for hypoxia and tissue microarrays are designed with sufficient core redundancy to represent hypoxic and perinecrotic areas [83] . Vleugel (Fig. 4A) [86] . By contrast, the patchy expression of carbonic anhydrase 9 in renal papillary carcinomas with wild-type VHL is secondary to hypoxia (Fig. 4B) [86] . [87] . By contrast, Generali and colleagues have reported that carbonic anhydrase 9, but not HIF-1␣ has prognostic significance in a series of breast cancers [68] . This might be due to HIF-1␣-independent regulation of carbonic anhydrase 9 [88] , but their expression was positively associated [68, 87] . Similarly, another group has reported disparity in the prognostic significance of hypoxia and several hypoxia-inducible proteins [89] . These results may be a reflection of the speed of induction and turnover (i.e. half-life) of these markers in response to hypoxia. HIF-1␣ protein stabilization is rapidly turned on and off, resulting in a short half-life measured in minutes [90] . By contrast carbonic anhydrase 9 is slow to accumulate and slow to turnover, with a half-life measured in hours [90] . Therefore, carbonic anhydrase 9 is a more sensitive marker of tissue hypoxia (it is more strongly associated with necrosis) [90, 91] (Fig. 5A, B) . Similarly, HIF-1␣ may be rapidly and strongly induced adjacent to early necrotic lesions, before expression of carbonic anhydrase 9 has been fully induced (Fig. 5C) [84] . This has implications for study design and interpretation, but is rarely considered in the methods or discussion of hypoxia marker studies.
The time taken to induce and turnover hypoxia markers influences their clinical significance. Winter and colleagues have reported that HIF-1␣, but not its transcriptional target carbonic anhydrase 9, has prognostic significance in a series of head and neck cancers
Quality of reports and analyses
The confusion in the literature may be explained, in part, by limitations in the conduct of tumour marker prognosis studies (many of which were published before the REMARK criteria were enforced) [92] [60] .
A re-analysis of the experimental data from the above study focused on the time dependency of hypoxia-regulated gene expression by human mammary epithelial cells [95] . The early response to hypoxia was characterized by genes concerned with growth, apoptosis, the insulin pathway, oestrogen receptor signalling and transcription factors such as ATF3 (a regulator of the unfolded protein response) [96] and BACH1 (a hypoxia-inducible repressor of hemoxygenase-1) [97] . The late response to hypoxia was similar to the signature identified by Chi and colleagues, and included genes involved in angiogenesis, glucose transport, proliferation, metabolism and apoptosis [95] [99] . While the hypoxia signature was a statistically significant adverse prognostic marker in several publicly available breast cancer datasets, high expression of the [84] . lactic acidosis response signature was associated with good prognosis, independent of the hypoxia signature [99] [99] . [103] , respectively. Furthermore, the hypoxic-regulation of several new genes comprised in this signature was experimentally confirmed in glioma cell lines and primary monocytes exposed to hypoxia [102] . Within the signature, several independent components were identified; among them, the relationship between hypoxia-modulated angiogenic genes and inflammatory genes was the only component associated with outcome in glioblastoma treated with chemoradiotherapy [102] .
Fig. 5 HIF-1␣ expression in ~50% of tumour cell nuclei (brown diaminobenzidine staining) from a clear cell renal carcinoma (A), in contrast to membranous carbonic anhydrase 9 (brown) expression iñ 100% of tumour cells in a serial section (B). Double staining for nuclear HIF-1␣ (brown) and membranous carbonic anhydrase 9 (blue) adjacent necrosis in a breast cancer (C). Bar ϭ 100 m. C, 40ϫ. (C) was reproduced with permission from reference
. The authors hypothesized that this may relate to the role of lactic acidosis in directing energy generation towards aerobic respiration, and utilization of other energy sources, via repression of glycolysis and Akt inhibition
In vivo clustering with seed genes
A data-mining approach to define a hypoxia signature in cancer in vivo has been explored by Winter and colleagues [100]. They derived an in vivo hypoxia metagene in head and neck squamous cell carcinoma (HNSCC) by clustering around the gene expression of a small set of hypoxia-regulated genes (e.g. carbonic anhydrase 9, glucose transporter-1 and VEGF) that have been well validated [19]. To minimize random association and falsepositive findings, new genes were included in the metagene only if they clustered with several hypoxia-regulated genes. This approach was chosen to identify genes that are missed in in vitro experiments, but may play an important role in the hypoxic response in vivo, where the situation is more complex, requiring consideration of multiple cell types, microenvironmental changes and three-dimensional complexity. For example, VEGF was not
MicroRNAs
MicroRNAs are small non-coding RNA sequences that are thought to regulate cellular processes by mechanisms including mRNA turnover, inhibition of translation, promoter activation and epigenetic silencing [104] . Recently, several hypoxia-inducible microRNAs have been identified [105, 106] . For example, Camps and colleagues profiled changes in microRNA expression in MCF7 breast cancer cells exposed to hypoxia to identify several novel hypoxia-inducible microRNAs [105] . Of these genes, has-miR-210 was reported to be an independent prognostic factor in breast cancer of a clinically significant margin (hazard ratio for overall survival 11.38, 95% confidence intervals 4.1 to 31.7) [105] . Thus, investigating the micro-RNA response to hypoxia in cancer, and its relation to clinical outcome, might provide useful complementary information to gene expression studies.
In summary, molecular signatures of the hypoxic response have shown in statistically and clinically significant prognostic potential (Table 1) . This is encouraging, but large discrepancies are present between signatures. In part, they might be due to a lack of standardization; although, standards such as MIAME [107] are continuously improving the reproducibility and transferability of results, and studies such as MACQC [108] 
Markers of hypoxia and response to treatment
Clinical data have shown a strong correlation between the degree and extent of tumour hypoxia and resistance to radiotherapy in certain tumour types (e.g. head and neck cancer, cervical cancer and soft-tissue sarcoma; reviewed in [109] ). Preclinical data suggest that radio-resistance is due, in part, to a preferentially prosurvival transcriptional response to HIF-1 expression by hypoxic cells [81, 110] [111] . However, retrospective subset analyses suggest that hypoxic tumours (identified by nuclear HIF-2␣ and/or membranous carbonic anhydrase 9 immunoreactivity) in this clinical trial were more resistant to CHART than conventional radiotherapy (interaction analysis, onetailed P ϭ 0.05) [112] . This is perhaps because CHART does not permit time for sufficient tumour re-oxygenation between doses, reducing radiation-induced cell death [112] .
Furthermore, data from three independent trials suggest that hypoxic tumours experience the greatest benefit from hypoxiamodifying therapy. The [114] . However, carbonic anhydrase 9 significantly predicted survival outcome in a singlearm phase II study of bevacizumab plus irinotecan in malignant astrocytoma [90] . Further work is necessary to determine whether this is a prognostic or a predictive association, and whether this observation applies to other cancer types.
Concluding remarks
Individual hypoxia markers have demonstrated independent prognostic significance in common tumour types, such as breast cancer [33] , and in settings where routine histopathological staging has failed to accurately inform the prognosis [61, 62] 
